Pomerantz Law Firm Launches Investigation into Rocket Pharmaceuticals for Investor Claims

Investor Alert: Investigation of Rocket Pharmaceuticals

Pomerantz LLP, a prominent law firm specializing in class action lawsuits, has recently announced its investigation into Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) on behalf of its investors. This comes amid concerns regarding potential securities fraud and other unlawful business practices involving the company and its executives.

The investigation comes in the wake of alarming news that was released on May 27, 2025. Rocket Pharmaceuticals made an announcement regarding its investigational gene therapy, RP-A501, which is aimed at treating Danon disease. Unfortunately, it was revealed that a participant in the Phase 2 pivotal trial of this therapy experienced what is classified as a Serious Adverse Event (SAE), specifically complications associated with capillary leak syndrome. As a precaution, Rocket Pharmaceuticals temporarily suspended dosage in the trial and the FDA subsequently imposed a clinical hold on the study for further assessment.

Tragically, the patient involved passed away due to an acute systemic infection following the SAE. Such news had a dramatic impact on the company’s stock prices. Following the report, Rocket’s shares plummeted by $3.94, which equates to a staggering 62.84% drop, closing at just $2.33 per share on the day of the announcement.

In light of these developments, investors are advised to take action. Those who have suffered losses as a result of their investments in Rocket Pharmaceuticals are encouraged to reach out to the firm to explore their legal options. Danielle Peyton, a representative of Pomerantz LLP, is available for inquiries and can provide information on joining any potential class action lawsuit.

Founded by Abraham L. Pomerantz, an influential figure in the arena of class action litigation, Pomerantz LLP has built a well-established reputation for advocating on behalf of shareholders facing injustices, including cases of securities fraud and corporate misconduct. The firm has been in operation for over 85 years and has successfully recovered numerous multimillion-dollar settlements on behalf of affected class members.

As this investigation unfolds, shareholders of Rocket Pharmaceuticals are encouraged to stay informed and prepared to engage in collective legal recourse as necessary. Legal action, particularly in securities fraud cases, can be complex, but firms like Pomerantz LLP stand ready to defend the rights of investors who find themselves affected by corporate malpractice.

For those interested in more information or looking to participate in the legal proceedings against Rocket Pharmaceuticals, please contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, extension 7980.

Disclaimer: This article serves solely for informational purposes and does not constitute legal advice. Prior results do not guarantee similar outcomes for future cases.